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Abstract
Background—Studies describing the incidence of Crohn’s disease (CD) and ulcerative colitis 
(UC) are uncommon in the United States (US). We sought to determine the incidence of CD and 
UC in the state of Rhode Island (RI).
Methods—The Ocean State Crohn’s and Colitis Area Registry (OSCCAR) is a state-based 
inception cohort of patients newly diagnosed with IBD in RI. To confirm a diagnosis of CD, UC or 
IBD unclassified (IBDU), the NIDDK IBD Genetics Consortium criteria were applied in a review 
of medical records from gastroenterology practices located in the state of RI and adjacent to the RI 
border in Massachusetts and Connecticut. Utilizing population-based data, we determined the 
statewide incidence of IBD in RI in 2008–2010.
Results—A total of 971 RI residents were diagnosed with IBD, including 444 with CD, 486 with 
UC and 41 with IBDU in 2008–2010. The overall age- and sex-adjusted IBD incidence was 30.2 
(95% CI, 28.3–32.1) per 100,000 persons in this time frame with 13.9, 15.1 and 1.3 per 100,000 
diagnosed with CD, UC and IBDU, respectively. Of the total incident cases in RI, 30% (n=291) 
were enrolled in OSCCAR for follow up.
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Conclusion—The incidence of IBD in RI is higher than that previously reported by other 
population-based cohorts in the US. Prospective follow up of individuals enrolled in the 
community-based OSCCAR cohort is ongoing.
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Introduction
Inflammatory bowel diseases (IBD), typically classified as either Crohn’s disease (CD) or 
ulcerative colitis (UC), are chronic, debilitating conditions characterized by relapsing and 
remitting episodes of gastrointestinal inflammation. As the incidence and prevalence have 
increased over the past 50 years, so has our understanding of the pathophysiology of this 
complex, immunologically-mediated disease process1–3. While various putative 
environmental risk factors have been implicated, an explanation for the increased rate of 
IBD diagnoses in the United States and abroad remains elusive4,5. Although data from 
developing countries are limited, recent reports suggest emergence of IBD as a global public 
health threat affecting newly industrialized nations in addition to more established, 
“westernized” populations5,6.
A recent systematic review by Molodecky, et al. presents a comprehensive overview of 
population-based data from all relevant epidemiologic studies published in Europe, Asia, the 
Middle East and North America between 1950–20107. While they report an estimated 
annual incidence rate of 19.2 per 100,000 persons of UC and 20.2 per 100,000 persons of 
CD in North America during this time frame, the US-specific data are mainly limited to 
findings reported from Olmsted County, Minnesota and a limited population of Northern 
California. In this light, the epidemiology of CD and UC has not been studied extensively in 
the United States (US). However, based on the available data from the US and Canada, these 
findings do suggest that the incidence and prevalence of IBD in North America are among 
the highest in the world.
In a review of the incidence and prevalence of the well-established cohort from Olmsted 
County, Loftus et al. reported the age and sex-adjusted annual incidence of UC and CD to be 
8.8 per 100,000 and 7.9 per 100,000, respectively over a 10-year period from 1990–20008. 
Herrinton, et al. reported annual incidence rates from the Kaiser Permanente Medical Care 
Program in Northern California between 1996–20029. While the observed incidence of CD 
of 6.3 per 100,000 persons in this population was less than that reported in Olmsted County 
during a similar period, the incidence of UC of 12.0 per 100,000 persons was significantly 
higher. In contrast, a report from the European collaborative study evaluating the incidence 
of IBD across 20 centers in Europe between 1991–1993, found an overall age- and sex-
adjusted incidence of 10.4 per 100,000 for UC and 5.6 per 100,000 for CD10. Thus, while 
the incidence of UC observed in California was similar to that in the European study, the 
incidence of CD appears to be higher, overall, in the US.
In Olmsted County, estimates are based on a unique medical records-linkage system (the 
Rochester Epidemiology Project) that captures approximately 90% of local residents. In 
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contrast, the Kaiser Permanente network provides care to an estimated 1/3 of the population 
in the San Francisco Bay region, Sacramento, and surrounding, less-urbanized communities. 
While Olmsted County is a relatively small, mostly Caucasian population, the Kaiser 
Permanente cohort represents a somewhat more diverse population. However, due to various 
geographic, demographic and methodological reasons, application of incidence data form 
these cohorts to the rest of the country may not be readily generalizable.
The Ocean State Crohn’s and Colitis Area Registry (OSCCAR), is a state-based, prospective 
inception cohort of patients with IBD diagnosed in the state of Rhode Island (RI). The 
relatively diverse population of over 1 million, limited geographic range and well-
circumscribed gastroenterology community were deemed to be excellent circumstances for 
establishing a prospective inception cohort of IBD patients in the US (see Supplemental 
Table 1). OSCCAR was originally designed to study the epidemiology of IBD, determine 
the incidence of IBD in RI and extrapolate these rates to the general population of the United 
States11. Utilizing population-based data obtained from OSCCAR we sought to estimate the 
statewide incidence of IBD in Rhode Island between 2008 and 2010.
Methods
Patient Enrollment
Overall, 97 of 98 practicing gastroenterologists and colorectal surgeons in Rhode Island 
agreed to refer patients to OSCCAR. Eleven gastroenterologists with practices in 
Massachusetts and Northern Connecticut just over the Rhode Island border also agreed to 
refer their newly diagnosed IBD patients who resided in Rhode Island. Enrollment began on 
January 1, 2008. All men, women, and children living in the state of Rhode Island with a 
newly confirmed diagnosis of CD, UC, or IBDU (inflammatory bowel disease, unspecified) 
were eligible for inclusion. Exclusion criteria included individuals diagnosed with CD, UC, 
or IBU prior to the study start date (i.e., prevalent cases), those unwilling or unable to 
provide informed consent for study participation and prisoners. Diagnosis of CD, UC, or 
IBDU was made by endoscopic, pathologic, or radiographic findings according to the 
criteria of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
IBD Genetics Consortium12. Institutional review board approval was obtained from all 
appropriate sites.
For those patients enrolled in OSCCAR, demographic, past medical history and disease-
related information was recorded via interview and completion of standardized 
questionnaires during study visits with trained personnel. All information was confirmed by 
review of medical records. Additional data elements (including results from imaging, 
endoscopy, pathology and operative reports) were recorded after data abstraction by trained 
personnel through standardized chart review of the participant’s medical record.
The Montreal classification system was used to describe disease phenotype at baseline13. 
Disease location in Crohn’s disease was designated as L1 (ileal), L2 (colonic), or L3 
(ileocolonic) with L4 as a modifier designating concomitant upper tract disease. Upper tract 
disease (L4) was based on endoscopic findings of inflammation and ulceration proximal to 
the ligament of Treitz. Behavior was defined as B1 (non-stricturing and non-penetrating), B2 
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(stricturing), or B3 (fistulizing/penetrating) with a P modifier to describe concomitant 
perianal disease. Ulcerative colitis disease location was described as E1 (proctitis), E2 (left 
sided disease), or E3 (pancolitis). Classifications were based on all available endoscopic, 
radiographic and surgical data obtained within 3 months of IBD diagnosis.
Ascertainment of Non-Enrolled Patients
To capture the total number of incident IBD cases in the state of Rhode Island between 
January 1, 2008 and December 31, 2010, exhaustive review of administrative (billing) data 
in participating practices was performed to identify patients with ICD-9 codes potentially 
mapping to IBD (see Supplemental Table II). At the time of data collection, not all practices 
in Rhode Island had adopted an electronic medical records system. In an effort to capture all 
diagnoses in a consistent manner, each practice’s respective billing system was queried for 
such diagnostic codes. A previously conducted survey of 432 primary care providers (PCP) 
in the state of Rhode Island determined that the majority of such practitioners would refer a 
patient with symptoms concerning for a new diagnosis of IBD to a specialist for further 
workup and management14. Thus, PCP records were not considered in our incidence 
calculation. Cases were confirmed by chart review performed by trained data abstractors 
(RB, MM, HM). These data were used to estimate the age- and sex-specific incidence of 
CD, UC and IBDU in Rhode Island in 2008–2010. Due to HIPPA limitations, only data 
related to IBD diagnosis, age at diagnosis, and gender were collected from the medical 
records of patients not enrolled in OSCCAR. Additional IBD-specific data, such as Montreal 
Classifications, were not recorded due to these restrictions.
Data Analysis
We calculated the median age at diagnosis and estimated the age- and sex-specific incidence 
of CD, UC and IBDU in Rhode Island in 2008–2010. Annual incidence was defined as the 
number of new cases per year per 100,000 persons in the population. We assumed all Rhode 
Island residents to be at risk, in total 1,050,788 in 2008, 1,057,329 in 2009 and 1,052,567 in 
201015. The denominator of incidence was derived from publicly available population 
statistics for the state of Rhode Island. We standardized the estimated incidence directly 
according to the age- and sex-distribution of the total US population, using the 2010 
Census16. The 95% confidence intervals (95% CI) for the age- and sex-adjusted incidence 
were calculated under the assumption that the number of IBD cases followed a Poisson 
distribution.
Results
Between 2008 and 2010, a total of 971 Rhode Island residents were diagnosed with IBD, 
including 444 with CD, 486 with UC and 41 with IBDU. Of those diagnosed with CD 193 
(43%) were male and 235 (48%) of those with UC were female. The median age at 
diagnosis was 35 years (range, 2 to 99) for CD and 44 years (range, 7 to 93) for UC. Age at 
diagnosis was unknown in 5 cases (0.5%).
Adjusting for age and sex, the estimated annual IBD incidence was 30.2 (95% CI, 28.3–
32.1) per 100,000 persons in the total population of Rhode Island in 2008–2010. There was 
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little variation noted during the 3 years studied. The incidence of IBD per 100,000 persons 
for 2008, 2009, and 2010 was 31.6, 30.4, and 30.3, respectively. Detailed data comparing 
enrolled and non-enrolled patients by year are presented in Supplementary Table 3. Table 1 
shows the incidence separately for CD, UC and IBDU by sex and age group. The incidence 
of CD was higher among the female residents than the male residents (15.3 vs. 12.5 per 
100,000 persons) while the incidence of UC was lower among females compared with males 
in Rhode Island (14.1 vs. 16.1 per 100,000 persons). Table 1 shows that the incidence 
proportions are greater for CD among the younger age groups, and for females aged 50–59 
as well. The cumulative age-specific incidence for IBD, CD, and UC is graphically 
represented in Figure 1.
Of the 971 incident cases in Rhode Island, 291 (30%) patients were enrolled in OSCCAR. 
Of those not enrolled, 111 (11%) patients with a confirmed diagnosis of IBD were either 
unresponsive to repeated communications or not interested in participation. An additional 35 
patients (4%) with a confirmed IBD diagnosis were deemed ineligible for study enrollment 
based on the exclusion criteria outlined above. The majority of these patients were either not 
Rhode Island residents or had been diagnosed with IBD for more than a year at the time of 
our chart review; two patients were incarcerated. While these patients did not meet inclusion 
criteria, they were considered in the incidence calculation if they resided in Rhode Island 
and were diagnosed with IBD between 2008 and 2010. Table 2 compares select 
demographic variables between enrolled and non-enrolled patients over the age of 18 years. 
In addition, disease location and behavior, as expressed by the Montreal Classification 
system, are presented for the OSCCAR cohort. The median age of diagnosis was 32.9 for 
those enrolled in OSCCAR versus 45.6 in the unenrolled patients. The observed younger age 
of OSCCAR is attributed to there being a single, academic Pediatric Gastroenterology 
practice in the state, of which the division chief (NSL) is a co-investigator of the study. 
During the 3-year timeframe, a total of 110 children under 18 were diagnosed with IBD, 84 
(76%) of which were enrolled in OSCCAR. When restricting the analysis to those over the 
age of 18 at diagnosis, the median age of those enrolled (40.7) versus non-enrolled (46.9) 
was not appreciably different (Table 2).
While 174 (60%) of the total OSCCAR cohort were diagnosed with CD, 109 (37%) and 8 
(3%) were diagnosed with UC and IBDU, respectively. Approximately half of the CD 
patients (n=87; 49%) presented with ileocolonic disease (L3). While the majority of CD 
patients (n=148; 83%) presented with inflammatory, non-stricturing, non-penetrating disease 
behavior (B1), 20% (n=36) and 10% (n=18) had concomitant upper tract and perianal 
disease, respectively at time of diagnosis. Half of those with UC (n=55; 50%) at enrollment 
presented with pancolitis (E3). Of those initially labeled IBDU, 6 (75%) have since been 
diagnosed with UC. Based on all available clinical information, the remaining 2 patients 
continue to meet diagnostic criteria for IBDU.
Discussion
In this near complete enumeration of IBD incident cases among the total population of 
Rhode Island, we found an overall age and sex-adjusted incidence of 30.2 per 100,000 
persons for IBD, 13.9 per 100,000 persons for CD and 15.1 per 100,000 persons for UC in 
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2008–2010. These incidences are within the highest quintile rank of published incidence 
rates worldwide7 and higher than those reported recently for specific populations in North 
America8,9,17. Similar to previous epidemiologic studies of IBD, we found a tendency 
towards a bi-modal age distribution7,18,19.
The estimated incidence of CD in Rhode Island was higher than the reported CD incidence 
of 7.9 (95% CI, 6.3–9.5) per 100,000 person-years Loftus et al. found in Olmsted County, 
Minnesota in 1990–20008 and considerably higher than the rate of 6.3 (95% CI, 5.6–7.0) per 
100,000 person-years Herrinton et al. demonstrated among members of Kaiser Permanente 
Medical Care Program in Northern California in 1996–20029. Similarly, our results indicate 
that UC was more commonly diagnosed among the residents of Rhode Island than in the 
study populations from Northern California (12.0, 95% CI, 11.0–13.0 per 100,000 person-
years)9 and Olmsted County, Minnesota (8.8, 95% CI, 7.2–10.5 per 100,000 person-years)8.
Population-based data from Olmsted County were obtained via retrospective review of a 
central medical records system that captures approximately 90% of local residents over a 3-
year period. In comparison to Rhode Island, Olmsted County represents a smaller, somewhat 
less diverse, higher-educated population. In addition to 90% of residents identifying as non-
Hispanic white, almost 30% are employed by the local health care system and are 1.5 times 
more likely to have a college education compared to the general population of the US8. 
Representing a larger, more diverse population, data from the Northern California cohort is 
limited to insurance claims from a single, albeit large, managed care organization. These 
data were limited to patients designated with an ICD-9 code for either CD (555.9) or UC 
(556.9) at a given clinical encounter. Accordingly, if a given condition is not addressed 
during the visit, the ICD-9 code is not recorded. Thus, in addition to the population being 
limited to members of a single health plan, there is a likelihood of missed cases given the 
narrow diagnostic criteria and fact that patients with inactive disease are less likely to be 
captured.
In contrast to the Olmsted County and Northern California cohorts, our data are reflective of 
nearly all new IBD diagnoses in the state of Rhode Island in 2008–2010. With cooperation 
from virtually all of the practicing gastroenterologists and general surgeons in the state and 
adjacent communities outside RI, OSCCAR began enrolling patients in January 2008. While 
not all patients diagnosed with IBD residing in Rhode Island were ultimately enrolled in the 
study, our incidence rates are based on a rigorous review of administrative billing data from 
all participating practices. A more thorough list of ICD-9 codes that may map to an IBD 
diagnosis was considered (see Supplemental Table II) and all cases were confirmed by chart 
review. In addition, a survey evaluating the referral patterns of primary care physicians in 
Rhode Island found that the majority of providers, when confronted with a patient with 
potential IBD, were very likely to refer to a specialist for further evaluation14. Thus, among 
the referral practices included, it is unlikely that many incident cases were missed. While 
practices in Massachusetts near the Rhode Island border that may care for Rhode Island 
residents were included, it is possible that some patients sought care out of state in practices 
not considered in our review.
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The high incidence of IBD we observed in Rhode Island is likely multifactorial in nature. As 
recent literature7 describes a steady increase in IBD diagnoses over time, it is possible that 
our cohort is reflective of this worldwide trend. Furthermore, the methodological rigor used 
to capture every diagnosis, regardless of enrollment in OSCCAR, is also a contributing 
factor. Given the well-defined geography of Rhode Island and thus accessibility of 
practitioner data, our cohort may more accurately reflect the true incidence of IBD in our 
study population as compared to larger populations such as Olmsted County and Northern 
California, where capturing each diagnosis represents a larger methodological challenge.
The population of the US in 2010 was approximately 309 million persons15. While the 
population of Rhode Island does not accurately reflect the population of the US as it relates 
to variations in geography, environmental exposures, and socioeconomic factors, if we were 
to extrapolate our estimated incidence in Rhode Island of 30.2 per 100,000 persons to the 
US population at that time, we would expect roughly 90,000 new cases of IBD (42–44,000 
CD cases; 46–48,000 UC cases) each year in the United States. Existing evidence suggests 
that both CD and UC are still more common among Caucasians than among African-
Americans, Asians and Hispanics, although the incidence of these diseases may be rising in 
these population segments20. We were unable to reliably ascertain race for patients not 
enrolled in OSCCAR. However, given the higher proportion of Caucasians living in Rhode 
Island compared with the US as a whole (81% versus the 72% in 2010; Suppl. Table I), the 
nationwide incidence of IBD might be somewhat lower than what we found in Rhode Island. 
We also note that smoking, identified as an important environmental factor in IBD with 
differing effects in UC and CD,21,22,23 may be less prevalent in Rhode Island than elsewhere 
in the US according to publicly available survey data24. This could distort an extrapolation 
of IBD incidence in Rhode Island to the total US population. Finally, our data cover newly 
diagnosed cases in Rhode Island over a three year period; hence our results could be affected 
by short term fluctuations in the statewide occurence of IBD.
Of the 971 patients newly diagnosed with IBD between 2008 and 2010, 291 (30%) were 
enrolled in OSCCAR. Thus, from an epidemiologic standpoint, OSCCAR represents a 
community-based cohort. However, there is only a single, academic Pediatric 
Gastroenterology practice in the state. As we enrolled 76% of new cases under 18 years of 
age at diagnosis, the pediatric segment of the OSCCAR cohort more closely represents a 
population-based sample. Of those enrolled, detailed clinical data related to disease 
phenotype, behavior, activity, treatment, outcomes and quality of life continue to be 
prospectively collected. In addition, biospecimens such as blood, urine and stool were 
obtained at study enrollment (diagnosis) and continue to be collected longitudinally. As 
prospective data collection from this novel cohort continues, OSCCAR represents a unique 
opportunity to study the natural history and course of IBD over time25–28. Other studies will 
continue to utilize the collected biospecimens to address translational questions29.
In conclusion, the observed incidence of IBD in Rhode Island is among the highest in the 
world. Ongoing prospective follow-up of individuals enrolled in the community-based 
OSCCAR cohort will provide a basis for predictive models of IBD prognosis over time.
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Table 2
Comparison of OSCCAR vs. Non-Enrolled Patients Newly Diagnosed with IBD in Rhode Island: 2008–2010#
OSCCAR
N=207#
Non-Enrolled Patients
N=654#
Age, (Mean, range) 40.8, 18–87 47, 18–99
Sex, N (%)
Male 85 (41) 320 (49)
Female 122 (59) 334 (51)
Race, N (%)
White 189 (91) N/A
African American 8 (4) N/A
Multiracial 3 (1) N/A
Other 6 (3) N/A
Refused/Unknown 1 (<1) 654 (100)
Ethnicity, N (%)
Not Hispanic or Latino 195 (94) N/A
Hispanic or Latino 11 (5) N/A
Refused/Unknown 1 (<1) 654 (100)
Diagnosis
CD, N (%) 111 (54) 251 (38)
Disease Location%
   L1 – Ileal 24 (22) N/A
   L2 – Colonic 33 (30) N/A
   L3 - Ileocolonic 53 (48) N/A
   L4*%-Upper tract 11 (10) N/A
Disease Behavior%
   B1 – Inflammatory 93 (84) N/A
   B2 – Stricturing 13 (12) N/A
   B3 – Penetrating 5 (5) N/A
   P* – Perianal 5 (5) N/A
UC, N (%) 91 (44) 368 (56)
   E1 – Proctitis 21 (23) N/A
   E2 – Left sided 28 (31) N/A
   E3 - Pancolitis 42 (46) N/A
IBDU, N (%) 5(2) 35(5)
*
Designates isolated or concomitant upper tract (L4) or concomitant perianal disease (P)
%
Designates that n=1 patients had isolated upper tract disease (L4) at diagnosis
#
Pediatric patients excluded (n=110) due to 76% enrollment in OSCCAR
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